FDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms associated with menopause, also referred to as hot flashes and night sweats.
FDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, also referred to as hot flashes and night sweats.
The British Menopause Society (BMS) on May 23 released updated recommendations on hormone replacement therapy (HRT), claiming that they are finally providing clarity to this murky issue. The new guidelines appear in the society’s flagship journal, Menopause International. Developed by a panel of experts, the guidelines discuss how women can optimize their menopause transition, focusing in particular on lifestyle and diet and the pros and cons of complementary therapies.
A new analysis from the SWAN study shows that anxiety before menopause does not correlate with anxiety during the menopausal transition. Researchers from the multisite Study of Women’s Health Across the Nation, report in Menopause that women who are calmer at premenopause actually are more susceptible to high anxiety during and after menopause than before menopause, and vice versa.
A registry-based study by researchers at UC San Francisco (UCSF) has shown an association between BRCA1/2 mutations and early menopause. The findings, published in Cancer, suggest that women who carry the genetic defect may be at risk of earlier infertility.